Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

Mirvetuximab soravtansine (MIRV) is a first-in-class antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) and is indicated for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to...

詳細記述

書誌詳細

主要な著者:	Andrew Hendershot, Mark Slabaugh, Kamran M. Riaz, Kathleen N. Moore, David M. O'Malley, Ursula Matulonis, Gottfried E. Konecny
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2023-06-01
シリーズ:	Gynecologic Oncology Reports
主題:	Ovarian cancer Antibody-drug conjugates Folate receptor alpha Mirvetuximab soravtansine Eye care Ocular adverse events
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2352578923000243
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!